Boskabadi Seyyed Javad, Farzameh Fatemeh, Mohammadnejad Kousar, Boskabady Mohammad Hossein
Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 15. doi: 10.1007/s00210-025-04276-8.
Herbal medicines have been proposed as adjuvant treatment for respiratory diseases. One such agent is Plantago major (P. major). Therefore, this review aims to gather the most recent experimental and clinical evidence on P. major's therapeutic effects on respiratory diseases. This review search was performed through Web of Science, PubMed, Google Scholar, and Scopus from the 1990s to March 2024. In experimental studies, the effects of P. major on inflammation, infection, asthma, and COPD models were established. In clinical studies, a significant reduction in cough and wheezing, increases in FEV1 and FVC in asthmatic patients, a rapid effect on signs and symptoms of bronchitis, and antiviral effects were observed. Despite in vitro and animal studies, there are limited clinical studies on the respiratory effects of P. major on humans. Therefore, designing more clinical studies to identify the respiratory effects of the plant and its derivatives should be considered.
草药已被提议作为呼吸系统疾病的辅助治疗方法。大车前草（Plantago major，P. major）就是这样一种药物。因此，本综述旨在收集关于大车前草对呼吸系统疾病治疗效果的最新实验和临床证据。本综述检索是通过科学网、PubMed、谷歌学术和Scopus从20世纪90年代到2024年3月进行的。在实验研究中，确定了大车前草对炎症、感染、哮喘和慢性阻塞性肺疾病（COPD）模型的影响。在临床研究中，观察到咳嗽和喘息显著减轻、哮喘患者第一秒用力呼气容积（FEV1）和用力肺活量（FVC）增加、对支气管炎的体征和症状有快速疗效以及抗病毒作用。尽管有体外和动物研究，但关于大车前草对人类呼吸系统影响的临床研究有限。因此，应考虑设计更多临床研究来确定该植物及其衍生物的呼吸系统影响。
